Alan Rapoport
Neurology · Los Angeles, CANPI 1922042480
Payments from drug & device makers
Across 793 payments — averaging $1018.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$238K
- Amgen$131K
- Teva Pharmaceuticals USA, Inc.$86K
- Biohaven Pharmaceutical Holding Company Ltd.$85K
- Biohaven Pharmaceuticals, Inc.$55K
- Pfizer$44K
- plus $168K from 19 others
Across 1 payment — averaging $3339.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$3K
What the payments were for
- Consulting fees$113,95214%
- Speaking & faculty fees$552,78568%
- Travel & lodging$113,58114%
- Food & beverage$15,5372%
- Education$11,7271%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 282 | $238,029 |
| Amgen | 135 | $131,164 |
| Teva Pharmaceuticals USA, Inc. | 76 | $85,518 |
| Biohaven Pharmaceutical Holding Company Ltd. | 99 | $84,658 |
| Biohaven Pharmaceuticals, Inc. | 71 | $55,480 |
| Pfizer(2 entities) | 22 | $44,466 |
| Dr.reddy's Laboratories,inc. | 11 | $37,545 |
| Otsuka Pharmaceutical Co., Ltd. | 12 | $21,949 |
| Impel Pharmaceuticals Inc. | 13 | $18,558 |
| Lundbeck LLC | 19 | $17,051 |
| H. Lundbeck A S | 6 | $16,033 |
| Axsome Therapeutics, Inc. | 11 | $14,079 |
| Amneal Pharmaceuticals LLC | 2 | $11,124 |
| Lilly USA, LLC | 11 | $10,376 |
| Upsher-smith Laboratories LLC | 6 | $5,444 |
| Biodelivery Sciences International, Inc. | 3 | $4,505 |
| Currax Pharmaceuticals LLC | 3 | $4,151 |
| Biogen | 2 | $3,463 |
| Collegium Pharmaceutical, Inc. | 2 | $2,400 |
| Tonix Medicines, Inc. | 1 | $1,300 |
| C2n Diagnostics, LLC | 1 | $142 |
| Eli Lilly | 2 | $90 |
| Janssen Scientific Affairs, LLC | 1 | $22 |
| Merz Pharmaceuticals, LLC | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$182,874
- NURTEC ODT$164,001
- AIMOVIG$129,458
- QULIPTA$106,174
- AJOVY$84,892
- Nerivio$37,545
- VYEPTI$32,807
- Trudhesa$18,490
- BREKIYA$11,100
- Symbravo$9,446
- ELYXYB - CELECOXIB$6,900
- Zembrace SymTouch Sumatriptan Injection$5,308
- Tosymra Sumatriptan Nasal Spray$5,308
- ONZETRA XSAIL$4,000
- BOTOX$3,375
- ZAVZPRET$3,000
- ZEMBRACE SYMTOUCH$1,300
- PRECIVITYAD2$142
How this compares
$807,582 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ajovy AutoinjectorFremanezumab-Vfrm | 20 | $17,216 |
Paid to pharmacies, not to this prescriber.
Other neurology in Los Angeles
- Timothy CloughesyLos Angeles$33.1M
- Perry ShiehLos Angeles$8.2M
- Jeffrey SaverLos Angeles$2.9M
- David PiccioniLos Angeles$2.9M
- David LiebeskindLos Angeles$2.7M
- Michele TagliatiLos Angeles$2.5M
- Jennifer HuiLos Angeles$2.4M
- Susan PerlmanLos Angeles$2.2M
- Jeffrey CummingsLos Angeles$2M
- Bryan SpannLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.